What are nanotherapeutics?


Nanotherapeutics are advanced medical treatments that use nanoscale particles, typically less than 100 nanometers in size, to deliver therapeutic compounds directly to targeted cells or tissues. This precision allows for enhanced effectiveness with reduced side effects compared to traditional treatments.

​

How do nanotherapeutics differ from standard medicine?


Traditional therapies circulate systemically, often affecting both healthy and diseased cells. Nanotherapeutics are engineered to seek out and bind to specific biological targets, such as cancer cells or inflamed tissue, allowing for controlled release and higher local concentrations of treatment where it matters most.

​

​

What kinds of conditions can nanotherapeutics help with?


Nanotherapeutics are used in areas such as oncology (targeted cancer therapy), regenerative medicine, autoimmune modulation, neuroprotection, and anti-aging.

​

​

What materials are used in your nanoparticles?


We primarily use biocompatible and biodegradable materials such as liposomes, polymeric nanoparticles, and exosome-like lipid vesicles. These materials are designed to safely degrade after delivering their therapeutic payload.

​

​

How are nanoparticles guided to specific tissues?


Nanoparticles can be surface-modified with targeting ligands, such as antibodies, peptides, or aptamers, that recognize receptors on specific cell types. This ensures the treatment localizes precisely where it is needed.

​

​

Do you use stem cells in combination with nanotherapeutics?


We can pair Wharton’s Jelly derived mesenchymal stem cell (WJ-MSC) exosomes or secretomes with nanoparticle systems to amplify regenerative and immunomodulatory effects.

​

​

Are these nanoparticles safe?


All nanoparticles used in our protocols are formulated from materials with established safety profiles.

​

​

​

​

Diagnostics & Personalization

​

What is a liquid biopsy, and how does it relate to nanotherapeutics?


A liquid biopsy analyzes circulating tumor cells, DNA, and exosomes in your blood. This allows us to identify molecular targets and design nanoparticle formulations that engage those pathways, enabling precision therapy without invasive tissue sampling.

​

​

How do you determine which nanotherapeutic protocol is right for me?


Based on your liquid biopsy results, our physicians design a nanotherapeutic protocol that delivers personalized therapies directly into cancer cells, mimicking a “Trojan Horse” approach.

​

​

​

​​

​

Treatment & Experience​

 

Can nanotherapeutics be used preventatively?


Yes. In longevity and wellness programs, nanoparticles can deliver antioxidants, NAD+ precursors, peptides, and mitochondrial enhancers to slow cellular aging and promote optimal performance.

​

​

Are there side effects?


Most patients experience minimal side effects, typically mild fatigue or temporary inflammation at the treatment site. Because nanoparticles allow for precise targeting, systemic toxicity is significantly reduced compared to conventional drugs.

​

​

What does a typical nanotherapeutic treatment look like?


Treatments are usually administered intravenously or through targeted injections, depending on the protocol.

​

​

How soon will I notice results?


Many patients report increased energy, reduced inflammation, or improved biomarkers within weeks. In regenerative and oncology applications, measurable results may take longer and are tracked through follow-up testing.

​

​

How many sessions will I need?


Protocols are tailored to your goals and biological response, ranging from a single targeted infusion to a multi-session program over several months.

Cost, Access & Logistics

​

​

How much do nanotherapeutic treatments cost?


Pricing depends on formulation complexity, number of sessions, and diagnostic requirements. Personalized treatment plans with transparent pricing are provided after consultation.

​

​

Is nanotherapeutic treatment covered by insurance?


Currently, personalized nanomedicine treatments are not covered by insurance, except through Samaritan Ministries, other other Christian Share Ministries. Financing options are available.

​

​

How does nanotherapy support longevity?


Nanotherapeutic approaches aim to improve cellular function, resilience, and signaling efficiency by enhancing delivery and bioavailability of therapeutic compounds at the cellular and subcellular level. Longevity-focused care may support mitochondrial health, reduce inflammatory burden, improve nutrient utilization, and promote more efficient repair mechanisms.

​

​

What are the long-term effects of nanotherapeutics?


Long-term human data on many nanotherapeutic modalities are still evolving. Evidence suggests that when appropriately formulated and dosed, many nano-delivery systems are well tolerated. Long-term outcomes depend on compound selection, delivery platform, dosing frequency, and patient biology. Ongoing monitoring and individualized risk assessment are essential.

​

​

​

Integration With Conventional Care​

 

Do you combine nanotherapeutics with other treatments?


Nanotherapeutic protocols are designed for optimal efficacy based on individual test results, pathology reports, and current scientific evidence. While other therapies may be synergistic, interactions can be complex and highly individualized.

​

​

Can I undergo nanotherapeutics while receiving chemotherapy or radiation?

In many cases, yes, but only with careful coordination. Patients undergoing chemotherapy and/or radiation are evaluated on a case-by-case basis, with direct communication between the treating oncologist and our medical team.

​​

​

​

​

​

Governance, Ethics & Expectations

​

​​Is this FDA-approved or experimental?


This program is investigational and adjunctive and is not FDA-approved as a cancer treatment. Components may involve FDA-approved substances used in non-standard, research, or supportive contexts under physician oversight and informed consent.

​

​

What oversight exists?


Care is delivered under formal clinical governance, including physician oversight, informed consent, protocolized care pathways, and institutional review where applicable. Patients are advised to remain under the care of their primary physician and oncologist.

​

​

What are the known risks?


Risks vary by intervention and may include infusion-related, metabolic, or immune- modulating effects. Therapies with known direct tumor-stimulatory risk or established oncologic contraindications are excluded.

​

​

How do you handle oncologist skepticism?


We encourage transparency, provide protocol summaries upon request, and defer all oncologic decision-making to the treating physician.

​

​​

​

​

​

Patient Fit & Outcomes

​

Who is not a candidate?


​Each individual is evaluated on a case-by-case basis.

​

​

Early-stage vs. late-stage patients, what’s different?


Goals differ. Early-stage patients focus on recovery and resilience, while late-stage patients focus on symptom support and quality of life.

​

​

Which cancers are most represented?


Participation is highest among solid tumors, including breast, colorectal, prostate, and gynecologic cancers. No cancer-specific efficacy is claimed.

​

​

How do you screen expectations?


Through informed consent, documented counseling, and repeated clarification that outcomes are uncertain and patient-specific.

​

​​

​

​

​

​

Data, Outcomes & Accountability

​

What outcomes do you track?


Tumor response, safety events, laboratory trends, symptom scores, functional status, adherence, and patient-reported outcomes.

​

​

How are results monitored?


Monitoring commonly includes circulating tumor cell (CTC) bloodwork and quarterly imaging when appropriate.

​

Would you like to know more?

Please reach out to our team and we will be happy to speak with you.